GWR Medical

What GWR Medical does

GWR Medical, Inc. is a privately held, family-controlled medical device company founded in 1996 and headquartered in Chadds Ford, Pennsylvania, that develops and supplies FDA-cleared Topical Oxygen Therapy (TO2) systems for treating non-healing chronic wounds and burns. The core technology applies low-pressure oxygen (1.03 atmospheres) directly to the wound site via two proprietary, one-time-use disposable devices — the O2Boot for extremities and the O2Sacral for torso and hard-to-reach areas — administered in a 90-minute daily protocol over four consecutive days followed by three days of rest. The therapy is supported by WoundMatrix, a proprietary mobile digital wound imaging and documentation platform founded in 2000 by the same CEO as a related enterprise, enabling physicians to measure, monitor, and report wound outcomes for payer reimbursement.

The company's revenue model centers on hardware sales of disposable TO2 devices prescribed by physicians and covered by Medicare, Medicaid, private insurers, the Veterans Administration, the Department of Defense (via Federal Supply Schedule and DAPA contracts), and Worker's Compensation programs. Distribution is primarily domestic (United States, with a stated Mid-Atlantic concentration) through an enterprise field sales motion in which sales representatives call on prescribing physicians and secure government contracts; the therapy itself is predominantly home-based, eliminating ambulatory and transportation costs. The leadership team comprises co-founders Sean M. Geary (President & CEO) and Paul A. Geary Jr. (Executive Chairman), with Paul A. Geary III as VP Sales and Richard J. Pinola as Advisor, and the Geary family maintains significant ownership and operational control. GWR has treated over 15,000 patients cumulatively and supported the largest independent topical oxygen therapy outcomes review (4,127 wounds over 9.5 years, published in Advances in Wound Care in 2017).

Name

GWR Medical

Legal name

GWR Medical, Inc.

Website

https://topicaloxygen.com

Company type

Private

Founded year

1996

Operating status

Operating

Headcount range

11–50 employees

Short description

GWR Medical is a privately held, FDA-cleared medical device company that develops and supplies disposable Topical Oxygen Therapy systems (O2Boot and O2Sacral) plus the WoundMatrix imaging platform for physicians treating patients with non-healing chronic wounds and burns, reimbursed across Medicare, Medicaid, VA, DoD, and private payers.

Ownership category

akta.pro rank

Product category

Wound Care Medical Devices

NAICS

Medical Equipment and Supplies Manufacturing (3391)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Negative Pressure Wound Therapy (NPWT) Systems & Accessories (HLAHALAB)

Keywords

• Topical oxygen therapy
• Wound care devices
• Chronic wound treatment
• Disposable medical devices
• Advanced wound management

Headquarters

HQ city

Chadds Ford

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Marketing or Sales, Supply Chain, Operations, Personnel, Technology or R&D, Others

Revenue model

1. TO2 Device Sales: One-time use disposable topical oxygen therapy devices (O2Boot and O2Sacral) sold to patients. Devices are prescribed by physicians and typically covered by insurance, Medicare, Medicaid, VA, DoD, and Worker's Compensation programs.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels4 records

Core offering

GWR Medical manufactures and supplies FDA-cleared Topical Oxygen Therapy (TO2) delivered through two disposable, single-use medical devices — the O2Boot® and O2Sacral® — that apply low-pressure oxygen directly to chronic, non-healing wounds at 1.03 atmospheres for 90 minutes per day in a 4-day-on/3-day-off cycle. The therapy is prescribed by wound-care physicians and primarily administered in the home setting, with reimbursement secured through private insurance, Medicare, Medicaid, VA/DoD, and Worker's Compensation. The WoundMatrix software platform supports wound measurement and outcomes documentation alongside the devices.

Product overview

GWR Medical offers a unified portfolio centered on FDA-cleared Topical Oxygen Therapy (TO2™) delivered through two portable, one-time use disposable devices: the O2Boot® for wounds on legs, arms, and hands, and the O2Sacral® for wounds on the torso, back, and thighs. The therapy is administered at 1.03 atmospheres of pressure for 90 minutes daily in a 4-day-on/3-day-off cycle. This core therapy is complemented by WoundMatrix, a proprietary mobile wound management imaging and measurement software platform that enables clinicians and patients to digitally measure wounds, monitor healing progress, and generate outcome documentation reports for doctors and insurers. Together, the TO2 devices and WoundMatrix software constitute the GWR Medical wound management program.

Differentiator

Problem solved

Functional benefit

Brands

• TO2™: Topical Oxygen Therapy brand for treating open wounds at 1.03 atmospheres of pressure
• O2Boot®
• O2Sacral®
• WoundMatrix

Quantifiable outcome

• Tissue pO2 of superficial wound tissue increased over 40mmHG within 4 minutes of topical oxygen application (2005 pig study)
• +2 more outcomes

Named customers5 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

One partnership is on record.

• WoundMatrixcoreStrategic or Co-development Partner · 1 January 2000Sean Geary founded WoundMatrix in 2000 as a related entity. WoundMatrix provides enterprise mobile and remote patient monitoring medical apps and software. GWR's TO2 therapy in conjunction with WoundMatrix mobile digital wound imaging apps and software tools measure, monitor and document wound outcomes. The GWR Medical Wound Management Program combines topical oxygen therapy with WoundMatrix for precise wound measurement and outcomes tracking documentation.

Scale indicators4 records

Recent moves5 records

Expansion highlights4 records

Direct peers

• EO2 Concepts: EO2 Concepts develops the TransCu O2 system, a topical oxygen therapy device for chronic wounds that competes head-to-head with GWR's O2Boot and O2Sacral. Both companies sell disposable, FDA-cleared topical oxygen chambers prescribed by wound care physicians in the US.
• AOTI Inc. AOTI is the most directly comparable competitor, also developing and commercializing topical oxygen therapy devices (e.g., the Natrox range) for chronic wound healing. Both companies target the same diabetic foot ulcer and chronic wound patient population with home-based oxygen delivery systems.
• Inotec AMD (Natrox Oxygen): Inotec AMD manufactures the Natrox continuous topical oxygen therapy system, a wearable device for chronic diabetic foot ulcers. It is one of the closest pure-play competitors to GWR's TO2 therapy in mechanism, indication, and home-use delivery model.

Emerging players

• OxyBand Technologies: OxyBand Technologies is an emerging player developing topical oxygen delivery wound dressings and devices. It overlaps with GWR's therapeutic modality but focuses on integrated dressing-plus-oxygen form factors rather than reusable chambers.

Broad incumbents

• Coloplast: Coloplast operates a sizable wound and skin care business alongside its core ostomy franchise. Its advanced wound dressings and skin substitute offerings target the same chronic-wound prescribers that GWR approaches through its physician sales force.
• Smith & Nephew: Smith & Nephew is a major global wound care incumbent whose Advanced Wound Management portfolio includes negative pressure wound therapy, antimicrobial dressings, and skin substitutes that compete for the same physician-prescribing budgets that GWR targets.
• Mölnlycke Health Care: Mölnlycke is a global wound care and surgical solutions incumbent with deep penetration in advanced dressings and negative pressure wound therapy. It competes for the same hospital and home-care wound management budget that GWR targets.
• 3M Health Care (Solventum): 3M's Health Care business, now operating as Solventum, owns a large advanced wound care portfolio including the Acelity/KCI negative pressure wound therapy franchise. It is a dominant incumbent competing for the same hospital, VA, and home-care wound patients as GWR.
• ConvaTec: ConvaTec is a broad wound care and ostomy incumbent with established relationships among wound care nurses, podiatrists, and hospital systems. Its portfolio of advanced dressings and NPWT competes for the same chronic-wound prescriptions that GWR seeks through O2Boot and O2Sacral.

Others

• WoundMatrix (as in-house platform comparison reference): WoundMatrix is GWR's own digital wound imaging subsidiary rather than an external competitor, but it illustrates the type of EMR-integrated wound documentation software (e.g., from Tissue Analytics or Swift Medical) that competes for the same clinician workflow. It is included as ecosystem context rather than as a true peer.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about GWR Medical